论文部分内容阅读
抗体药物的成功应用大大延长了很多乳腺癌女性患者的生命。将一种药物描述成为革命性的、改变性的或一个本垒打,这些词汇通常是用作新闻稿或报告给投资者的。但是肿瘤学家却更愿意用这样的语言来描述两种药物:这是两种可以为一些乳腺癌患者提供治疗而不仅仅是安慰的药物。这两种药物分别是曲妥珠单抗(赫赛汀)和帕妥珠单抗(Perjeta)。这两个免疫抗体制剂都靶向作用于信号蛋白HER2上,HER2是在20%~25%的乳腺癌
The successful use of antibody drugs has greatly extended the lives of many women with breast cancer. Describing a drug as revolutionary, changing or a home run is often used as a press release or report to investors. But oncologists are more willing to describe two drugs in such a language: two drugs that can provide treatment, not just comfort, to some breast cancer patients. The two drugs are trastuzumab (Herceptin) and Perjeta respectively. Both immune antibody preparations are targeted to the signal protein HER2, HER2 is in 20% to 25% of breast cancer